[{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Mycenax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"SK Holdings, Heritas Capital, SEEDS Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"HMBD-001","moa":"HER3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Novo Holdings"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Novogene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Merck"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"HMBD-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"George Clinical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"HMBD-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ George Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ George Clinical"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Endeavor Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HMBD-501","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.42999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Endeavor BioMedicines","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Endeavor BioMedicines"}]

Find Clinical Drug Pipeline Developments & Deals by Hummingbird Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).

                          Brand Name : HMBD-501

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 19, 2023

                          Lead Product(s) : HMBD-501

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Endeavor Biomedicines

                          Deal Size : $430.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the collaboration, Hummingbird will evaluate its potentially best-in-class HER3-targeting antibody, HMBD-001, in combination with SoC chemotherapy with or without Merck's cetuximab, anti-EGFR mAb, in patients with sqNSCLC in a Phase 1b clinical tri...

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 15, 2023

                          Lead Product(s) : HMBD-001,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : George Clinical will provide its full-service CRO expertise for the Hummingbird sponsored trials, including HMBD-001, a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3, developed with its Rational Antibo...

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 04, 2023

                          Lead Product(s) : HMBD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : George Clinical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : HMBD-001 is an anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with H...

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 06, 2023

                          Lead Product(s) : HMBD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 04, 2023

                          Lead Product(s) : Antibody-drug Conjugate-based Therapy

                          Therapeutic Area : Technology

                          Highest Development Status : Preclinical

                          Recipient : Synaffix

                          Deal Size : $150.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : HMBD-002 is an investigational IgG4 anti-VISTA antagonist antibody to target the region where VISTA interacts with binding partners that have been shown to play an important role in modulating T cell activity, potentially unlocking the immune system to a...

                          Brand Name : HMBD-002

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 19, 2022

                          Lead Product(s) : HMBD-002,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under this collaboration, Hummingbird will evaluate the safety, tolerability, and anti-tumor activity of its novel anti-VISTA antibody, HMBD-002, in combination with KEYTRUDA ® (pembrolizumab).

                          Brand Name : HMBD-002

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 25, 2021

                          Lead Product(s) : HMBD-002,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : HMBD-001 is a novel antibody with a unique, differentiated mechanism of action that fully inhibits HER3 activation of the MAPK/PI3K tumor growth signaling pathway.

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 02, 2021

                          Lead Product(s) : HMBD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Partnership will leverage Novogene’s strong molecular diagnostics capabilities to expand patient identification through Next Generation Sequencing, NGS, testing in China to support the development of Hummingbird Bioscience’s investigational drug cand...

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 09, 2021

                          Lead Product(s) : HMBD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Novogene

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Proceeds from the financing will be used to advance the clinical development of Hummingbird’s lead assets including, HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, an anti-VISTA neutralizing antibody.

                          Brand Name : HMBD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 18, 2021

                          Lead Product(s) : HMBD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Novo Holdings

                          Deal Size : $125.0 million

                          Deal Type : Series C Financing

                          blank